Pages that link to "Q43775906"
Jump to navigation
Jump to search
The following pages link to Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report (Q43775906):
Displaying 50 items.
- Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents (Q21198868) (← links)
- Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress (Q23918915) (← links)
- Histone deacetylases (HDACs): characterization of the classical HDAC family (Q24535587) (← links)
- Macrocyclic histone deacetylase inhibitors (Q24629065) (← links)
- A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma (Q24658533) (← links)
- Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response (Q24675625) (← links)
- Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study (Q24810933) (← links)
- Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future (Q26746934) (← links)
- DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics (Q26749421) (← links)
- Romidepsin for the Treatment of Peripheral T-Cell Lymphoma (Q26785732) (← links)
- Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications (Q26853394) (← links)
- Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy (Q28082536) (← links)
- Chemogenomics: an emerging strategy for rapid target and drug discovery (Q28260664) (← links)
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer (Q29615649) (← links)
- Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data (Q30936712) (← links)
- Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1). (Q33235403) (← links)
- Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors (Q33364474) (← links)
- Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma (Q33381498) (← links)
- Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat. (Q33385966) (← links)
- Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma (Q33386623) (← links)
- Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. (Q33390876) (← links)
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma (Q33394324) (← links)
- Romidepsin for the treatment of T-cell lymphomas (Q33408509) (← links)
- Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma (Q33417976) (← links)
- Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection (Q33476165) (← links)
- Immunopathogenesis and therapy of cutaneous T cell lymphoma (Q33726963) (← links)
- Epigenetic changes in the myelodysplastic syndrome. (Q33767309) (← links)
- Fluid shear stress stimulates phosphorylation-dependent nuclear export of HDAC5 and mediates expression of KLF2 and eNOS (Q33788731) (← links)
- The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines (Q34015778) (← links)
- Identification and characterization of novel sirtuin inhibitor scaffolds (Q34088797) (← links)
- Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. (Q34171631) (← links)
- Histone modification enzymes: novel targets for cancer drugs (Q34322087) (← links)
- Targeting histone deacetyalses in the treatment of B- and T-cell malignancies (Q34414452) (← links)
- Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma (Q34441748) (← links)
- The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo (Q34504770) (← links)
- Biotechnologies and therapeutics: chromatin as a target. (Q34563296) (← links)
- New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies (Q34683488) (← links)
- Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma (Q34729026) (← links)
- Macrocyclic drugs and synthetic methodologies toward macrocycles (Q34740721) (← links)
- Histone-deacetylase inhibitors: novel drugs for the treatment of cancer (Q34743301) (← links)
- Mycosis fungoides and Sézary syndrome (Q34761883) (← links)
- Alterations of DNA methylation in hematologic malignancies (Q34762188) (← links)
- Impact of ABCB1 allelic variants on QTc interval prolongation (Q34781769) (← links)
- Histone deacetylase inhibitors: from target to clinical trials (Q35011880) (← links)
- Epigenetics in cancer: implications for early detection and prevention (Q35021339) (← links)
- Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome) (Q35022833) (← links)
- Histone deacetylase inhibitors with enhanced enzymatic inhibition effects and potent in vitro and in vivo antitumor activities (Q35042270) (← links)
- Cell-cycle dysregulation and anticancer therapy (Q35082170) (← links)
- Epigenetics and the Environment (Q35118498) (← links)
- Epigenetic Changes: Potential Therapeutic Targets (Q35118544) (← links)